Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 91Neoplasm Metastasis 11Prostate Cancer Metastatic 4Oligometastatic Prostate Cancer 3Adenocarcinoma 3Radiation Injuries 2Prostatic Diseases 2Prostate CA 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Urologic Diseases 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1Non-metastatic, Hormone naïve Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Castration-resistant Prostate Cancer 1Lymphatic Metastasis 1Intraprostatic Prostate Cancer 1Insulin Resistance 1Hormone Sensitive Prostate Cancer 1Genital Diseases, Male 1

Interventions

pexidartinib 1bicalutamide 1Raloxifene Hydrochloride 1Radiotherapy 1Radiosurgery 1Radiation 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stage I Prostate Adenocarcinoma × Androgen Antagonists × Clear all
NCT02472275 2020-10-06

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
8 enrolled
Genitourinary

Stage I Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡